Study S001631

A Randomized, Double-blind, Single-centre, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between the Phase 2 Formulation of Liraglutide at pH 7.7 (Formulation 3) and the Phase 3 Formulation at pH 8.15 (Formulation 4)

ClinicalTrials.gov record

Registration

Registration: NCT01515579
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 22
Start: 2006-04
Primary completion: 2006-06
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Healthy
Interventions: DRUG:liraglutide
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2005-005948-68; NIH:2005

Registered primary outcomes

Area under the curve (0-t) []
Cmax, maximum concentration []

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.